Inhibikase Therapeutics, Inc. (IKT)
NASDAQ: IKT · Real-Time Price · USD
1.900
-0.080 (-4.04%)
Apr 17, 2025, 4:00 PM EDT - Market closed
Inhibikase Therapeutics Market Cap
Inhibikase Therapeutics has a market cap or net worth of $141.25 million as of April 17, 2025. Its market cap has increased by 914.34% in one year.
Market Cap
141.25M
Enterprise Value
43.82M
1-Year Change
914.34%
Ranking
Category
Stock Price
$1.90
Market Cap Chart
Since the IPO on December 23, 2020, Inhibikase Therapeutics's market cap has increased from $100.46M to $141.25M, an increase of 40.61%. That is a compound annual growth rate of 8.21%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Apr 17, 2025 | 141.25M | -35.32% |
| Dec 31, 2024 | 218.38M | 2,684.93% |
| Dec 29, 2023 | 7.84M | -37.83% |
| Dec 30, 2022 | 12.61M | -65.89% |
| Dec 31, 2021 | 36.98M | -46.68% |
| Dec 31, 2020 | 69.35M | -30.96% |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Eli Lilly and Company | 754.27B |
| UnitedHealth Group | 415.38B |
| Johnson & Johnson | 379.48B |
| AbbVie | 306.02B |
| Novo Nordisk | 284.50B |
| Abbott Laboratories | 227.16B |
| Novartis AG | 209.93B |
| AstraZeneca | 208.11B |